ChromoCure, Inc.
ChromoCure, Inc. (KKUR) Stock Overview
Explore ChromoCure, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.2K
P/E Ratio
N/A
EPS (TTM)
N/A
ROE
N/A
KKUR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of ChromoCure, Inc. (KKUR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 8.2K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
ChromoCure, Inc. develops and provides proprietary cancer detection systems. The company offers Chromosomal Scanner Series 200, a cancer detection system to measure the genomic characteristic found in 100% of all cancers and never found in normal cells. It also applies its science and technology to non-toxic and non-invasive approaches to cancer therapy and cure research. The company was formerly known as Cyberhand Technologies International, Inc. and changed its name to ChromoCure, Inc. in June 2009. ChromoCure, Inc. was incorporated in 2001 and is based in Reno, Nevada.
4
Reno
2005